Targets › C5AR1
1 program from 1 company in 4 trials: 2 Phase 4, 1 Phase 3, 1 Phase 2; Immunology; next expected readout Jul 2027.
Receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a, stimulating chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. (UniProt, P21730)
Open in Phaseline: the race on C5AR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Amgen | Avacopan C5a anaphylatoxin chemotactic receptor antagonist | C5AR1 | Phase 4 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis; Vasculitis; ANCA Associated Vasculitis (AAV); Granulomatosis With Polyangiitis | Jul 2027 |
Antineutrophil Cytoplasmic Antibody-associated Vasculitis (1) Vasculitis (1) ANCA Associated Vasculitis (AAV) (1) Granulomatosis With Polyangiitis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.